- Home
- FBIOP vs NAMS Comparison
FBIOP vs NAMS Comparison
Compare FBIOP & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBIOP
- NAMS
- Stock Information
- Founded
- FBIOP N/A
- NAMS 2019
- Country
- FBIOP United States
- NAMS Netherlands
- Employees
- FBIOP 186
- NAMS N/A
- Industry
- FBIOP Biotechnology: Pharmaceutical Preparations
- NAMS Biotechnology: Pharmaceutical Preparations
- Sector
- FBIOP Health Care
- NAMS Health Care
- Exchange
- FBIOP Nasdaq
- NAMS Nasdaq
- Market Cap
- FBIOP N/A
- NAMS N/A
- IPO Year
- FBIOP N/A
- NAMS N/A
- Fundamental
- Price
- FBIOP $5.75
- NAMS $18.21
- Analyst Decision
- FBIOP
- NAMS Strong Buy
- Analyst Count
- FBIOP 0
- NAMS 7
- Target Price
- FBIOP N/A
- NAMS $43.17
- AVG Volume (30 Days)
- FBIOP N/A
- NAMS 1.3M
- Earning Date
- FBIOP N/A
- NAMS 05-05-2025
- Dividend Yield
- FBIOP N/A
- NAMS N/A
- EPS Growth
- FBIOP N/A
- NAMS N/A
- EPS
- FBIOP N/A
- NAMS N/A
- Revenue
- FBIOP N/A
- NAMS $45,563,000.00
- Revenue This Year
- FBIOP N/A
- NAMS N/A
- Revenue Next Year
- FBIOP N/A
- NAMS N/A
- P/E Ratio
- FBIOP N/A
- NAMS N/A
- Revenue Growth
- FBIOP N/A
- NAMS 223.37
- 52 Week Low
- FBIOP N/A
- NAMS $15.19
- 52 Week High
- FBIOP N/A
- NAMS $27.29
- Technical
- Relative Strength Index (RSI)
- FBIOP 35.47
- NAMS 27.08
- Support Level
- FBIOP $5.50
- NAMS $22.05
- Resistance Level
- FBIOP $6.74
- NAMS $24.51
- Average True Range (ATR)
- FBIOP 0.27
- NAMS 1.25
- MACD
- FBIOP -0.08
- NAMS -0.66
- Stochastic Oscillator
- FBIOP 20.00
- NAMS 8.36
About FBIOP Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors.